Short Article Open Access

Secukinumab for recalcitrant Psoriatic Arthritis cases

Abstract

In the pre-TNF inhibitors (TNFi) era, several recalcitrant, moderate-to-severe, psoriatic arthritis (PsA) cases have been reported [1, 2]. The available treatment options were glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), retinoids, and photochemotherapy, but the results were modest [3]. TNFi revolutionised the treatment for PSA, with a constant decline of the recalcitrant cases [4, 5]. TNFi are biologic disease-modifying antirheumatic drugs (bDMARDs) bearing a significant capacity to achieve low disease activity or remission having an appealing efficacy/safety profile [6, 7]. The first TNFi for moderate-to-severe PsA was etanercept [8]. Nowadays, several bDMARDs(adalimumab, infliximab, golimumab, certolizumabpegol, ustekinumab, secukinumab, ixekizumab) and targeted synthetic DMARDs are already available such astofacitinibandapremilast.

Pelechas E, Voulgari PV, Drosos AA

To read the full article Download Full Article